Review
BibTex RIS Cite

PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ

Year 2016, Supplement 16, 108 - 113, 24.11.2016
https://doi.org/10.17567/ataunidfd.290590

Abstract

ÖZ



Sağlığın
devam ettirilebilmesi için akut enflamatuvar yanıtın tamamen çözülmesi ve
vücudun homeostazise dönmesi gerekmektedir. Enflamatuvar yanıtta rol alan
lökositlerin, ortamda ölü hücre ve ürünlerini bırakma- yacak şekilde
kaldırılması ideal sonuç olmakla birlikte periodontal hastalıkta ve birçok
farklı sistemik hasta- lıkta, benzer şekilde kontrol altına alınamayan ve çözü-
lememiş bir enflamatuvar durumun oluştuğu görülmektedir.



Bugüne
kadar çalışılan antienflamatuvar ajanlardan steroidler, steroid olmayan
antienflamatuvar ilaçlar ve antihistaminikler, akut enflamatuvar yanıtın
başlama- sında rol alan anahtar proenflamatuvar medyatör yollarını bloke
ederler ve enflamasyonun kardinal bulgularının kontrolünde rol almaktadırlar.
Bu terapötik yaklaşım, birçok enflamatuvar hastalığın tedavisinde temel konumda
yer alsa da beraberinde oluşan yan etkilerin de göz ardı edilmemesi gerektiği
bir gerçektir.



Son
yıllarda, enflamasyonla ilişkili moleküler temellerin ortaya konulmasıyla
birlikte, enflamasyonun çözülme- sinin aktif ve
agonist ilişkili
bir süreç olduğu ve doku homeostazisine dönüşün çok dikkatli bir şekilde düzen-
lendiği anlaşılmıştır. Enflamasyonun çözülmesinin yeni bir sınıf olan ileri
basamak çözücü lipid medyatörleri (İBÇLM) tarafından düzenlendiğinin
anlaşılmasıyla birlikte, periodontal patolojinin önlenmesinde ve enfla- matuvar
lökositlerin eliminasyonunda, İBÇLM molekül- lerinin potansiyel kullanımlarına
olan ilginin arttığı görülmektedir.



Bu
derlemede, İBÇLM’lerin enflamatuvar süreçte ve periodontal hastalık
patogenezindeki önemi ortaya konulmaya çalışılmıştır.



Anahtar sözcükler: Periodontal
hastalıklar, inflamasyon, yağ asidleri

 



A NEW APPROACH IN PERIODONTAL TREATMENT: PRORESOLVING LIPID MEDIATORS

ABSTRACT

 

Complete resolution of acute inflammatory response and
returning the body to homeostasis is crucial for on-going health. Although
removing of leukocytes in inflammation area without leaving any dead cells or
their products behind is an ideal result, it appears that uncontrolled and
unresolved inflammatory condition occurs in periodontal disease and various
systemic diseases similarly.

Most of the antiinflammatory agents studied up to now
such as steroids, non-steroid antiinflammatory drugs and antihistamines bloke
key proinflammatory mediator ways in the initiation of acute inflammatory
response or take part in the control of the cardinal symptoms. Despite this
therapeutic approach is a basic principle for the treatment of many inflammatory
diseases, it’s clear that adverse effects should not be ignored.  

Recently, after the determination of the inflammatory
basics, we understood that inflammatory resolution is an active and agonist
related process and returning to the tissue homeostasis is arranged very
carefully. Together with the understanding of the inflammatory resolution is
arranged by new classification of proresolving lipid mediators (PRLMs), the
interest on these molecules related to the prevention of periodontal pathology and
elimination of inflammatory leukocytes have increased.

In this review, we aimed to put forward the importance
of the PRLMs on the inflammatory process and periodontal pathogenesis.  













Keywords: Periodontal diseases, inflammation, fatty acids

References

  • Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-63.
  • 2. Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhasker V, Gordillo GM, Sen CK, Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 2010;5:e9539.
  • 3. Hutchinson JL, Rajagopal SP, Sales KJ, Jabbour HN. Molecular regulators of resolution of inflammation: potential therapeutic targets in the reproductive system. Reproduction 2011;142:15-28.
  • 4. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007;179:7021-9.
  • 5. Bhatavadekar NB, Williams RC. Modulation of the host inflammatory response in periodontal disease management: exciting new directions. Int Dent J 2009;59:305-8.
  • 6. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61.
  • 7. Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S. Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. Periodontol 2000 2006;40:130-43.
  • 8. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21:325-32
  • 0. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010;177:1576-91.
  • 11. Grover V, Malhotra R, Kapoor A, Singh J, Sachdeva S. Proresolution mediators and receptors: novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation. Infect Disord Drug Targets 2013;13:75-84.
  • 12. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007;447:869-74.
  • 13. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, Henson PM. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem 2006;281:38376-84.
  • 14. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-37.
  • 15. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278:14677-87.
  • 16. Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J 2007;21:3162-70.
  • 17. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008;3:99-126.
  • 18. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005;174:4345-55.
  • 19. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9:873-9
  • 29. Kantarci A, Van Dyke TE. Lipoxins in chronic inflammation. Crit Rev Oral Biol Med 2003;14:4-12.
  • 30. Yıldırım TT, Kaya FA. Agresif Periodontitis. Atatürk Üniv Diş Hek Fak Derg 2011;4:15-23.
  • 31. Elabdeen HR, Mustafa M, Szklenar M, Ruhl R, Ali R, Bolstad AI. Ratio of pro-resolving and pro-inflammatory lipid mediator precursors as potential markers for aggressive periodontitis. PLoS One 2013;8:e70838.
  • 32. Kantarci A, Oyaizu K, Van Dyke TE. Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003;74:66-75.
  • 33. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J 2006;20:401-3.
  • 34. Dogan B, Fentoglu O, Kirzioglu FY, Kemer ES, Koroglu BK, Aksu O, Carsancakli SA, Orhan H. Lipoxin A4 and Neutrophil/Lymphocyte Ratio: A Possible Indicator in Achieved Systemic Risk Factors for Periodontitis. Med Sci Monit 2015;21:2485-93.
  • 35. Freire MO, Van Dyke TE. Natural resolution of inflammation. Periodontol 2000 2013;63:149-64.
Year 2016, Supplement 16, 108 - 113, 24.11.2016
https://doi.org/10.17567/ataunidfd.290590

Abstract

References

  • Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-63.
  • 2. Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhasker V, Gordillo GM, Sen CK, Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 2010;5:e9539.
  • 3. Hutchinson JL, Rajagopal SP, Sales KJ, Jabbour HN. Molecular regulators of resolution of inflammation: potential therapeutic targets in the reproductive system. Reproduction 2011;142:15-28.
  • 4. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007;179:7021-9.
  • 5. Bhatavadekar NB, Williams RC. Modulation of the host inflammatory response in periodontal disease management: exciting new directions. Int Dent J 2009;59:305-8.
  • 6. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61.
  • 7. Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S. Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. Periodontol 2000 2006;40:130-43.
  • 8. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21:325-32
  • 0. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010;177:1576-91.
  • 11. Grover V, Malhotra R, Kapoor A, Singh J, Sachdeva S. Proresolution mediators and receptors: novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation. Infect Disord Drug Targets 2013;13:75-84.
  • 12. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007;447:869-74.
  • 13. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, Henson PM. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem 2006;281:38376-84.
  • 14. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-37.
  • 15. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278:14677-87.
  • 16. Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J 2007;21:3162-70.
  • 17. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008;3:99-126.
  • 18. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005;174:4345-55.
  • 19. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9:873-9
  • 29. Kantarci A, Van Dyke TE. Lipoxins in chronic inflammation. Crit Rev Oral Biol Med 2003;14:4-12.
  • 30. Yıldırım TT, Kaya FA. Agresif Periodontitis. Atatürk Üniv Diş Hek Fak Derg 2011;4:15-23.
  • 31. Elabdeen HR, Mustafa M, Szklenar M, Ruhl R, Ali R, Bolstad AI. Ratio of pro-resolving and pro-inflammatory lipid mediator precursors as potential markers for aggressive periodontitis. PLoS One 2013;8:e70838.
  • 32. Kantarci A, Oyaizu K, Van Dyke TE. Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003;74:66-75.
  • 33. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J 2006;20:401-3.
  • 34. Dogan B, Fentoglu O, Kirzioglu FY, Kemer ES, Koroglu BK, Aksu O, Carsancakli SA, Orhan H. Lipoxin A4 and Neutrophil/Lymphocyte Ratio: A Possible Indicator in Achieved Systemic Risk Factors for Periodontitis. Med Sci Monit 2015;21:2485-93.
  • 35. Freire MO, Van Dyke TE. Natural resolution of inflammation. Periodontol 2000 2013;63:149-64.
There are 25 citations in total.

Details

Subjects Health Care Administration
Journal Section Articles
Authors

Burak Doğan

Esra Sinem Kemer Doğan This is me

Behiye Bolgül This is me

Publication Date November 24, 2016
Published in Issue Year 2016 Supplement 16

Cite

APA Doğan, B., Kemer Doğan, E. S., & Bolgül, B. (2016). PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi108-113. https://doi.org/10.17567/ataunidfd.290590
AMA Doğan B, Kemer Doğan ES, Bolgül B. PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ. Ata Diş Hek Fak Derg. Published online November 1, 2016:108-113. doi:10.17567/ataunidfd.290590
Chicago Doğan, Burak, Esra Sinem Kemer Doğan, and Behiye Bolgül. “PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ”. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, November (November 2016), 108-13. https://doi.org/10.17567/ataunidfd.290590.
EndNote Doğan B, Kemer Doğan ES, Bolgül B (November 1, 2016) PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi 108–113.
IEEE B. Doğan, E. S. Kemer Doğan, and B. Bolgül, “PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ”, Ata Diş Hek Fak Derg, pp. 108–113, November 2016, doi: 10.17567/ataunidfd.290590.
ISNAD Doğan, Burak et al. “PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ”. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi. November 2016. 108-113. https://doi.org/10.17567/ataunidfd.290590.
JAMA Doğan B, Kemer Doğan ES, Bolgül B. PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ. Ata Diş Hek Fak Derg. 2016;:108–113.
MLA Doğan, Burak et al. “PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ”. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, 2016, pp. 108-13, doi:10.17567/ataunidfd.290590.
Vancouver Doğan B, Kemer Doğan ES, Bolgül B. PERİODONTAL TEDAVİDE YENİ YAKLAŞIM: İLERİ BASAMAK ÇÖZÜCÜ LİPİD MEDYATÖRLERİ. Ata Diş Hek Fak Derg. 2016:108-13.

Bu eser Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır. Tıklayınız.